The biotech firm reported increased cash burn in Q1 2026, with operating activities consuming $3.2 million.
Revelation Biosciences reported a first-quarter GAAP loss of $2.71 per share, reflecting ongoing operational costs. The company’s net cash used for operating activities rose to $3.2 million for the three months ended March 31, 2026, up from $2.8 million in the same period last year.
The increase in cash burn highlights elevated spending as the firm advances its pipeline. No immediate market reaction was disclosed in the release.